ClinicalTrials.gov record
Not yet recruiting Phase 4 Interventional

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

ClinicalTrials.gov ID: NCT07357597

Public ClinicalTrials.gov record NCT07357597. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IV, Open-Label, Single-Arm Study of Prophylaxis for Datopotamab Deruxtecan-related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer (TROPION-SWISH)

Study identification

NCT ID
NCT07357597
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 4
Lead sponsor
AstraZeneca
Industry
Enrollment
100 participants

Conditions and interventions

Conditions

Interventions

  • Datopotamab Deruxtecan (Dato-DXd) Drug
  • Dexamethasone mouthwash Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 26, 2026
Primary completion
Oct 8, 2027
Completion
Oct 8, 2027
Last update posted
Jan 21, 2026

2026 – 2027

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
Research Site Tucson Arizona 85719
Research Site Hot Springs Arkansas 71913
Research Site Little Rock Arkansas 72205
Research Site Duarte California 91010
Research Site Glendale California 91204
Research Site Lakewood California 90805
Research Site Torrance California 90505
Research Site Athens Georgia 30607
Research Site Park Ridge Illinois 60068
Research Site Fort Wayne Indiana 46825
Research Site Lexington Kentucky 40503
Research Site Louisville Kentucky 40207
Research Site Detroit Michigan 48202
Research Site Reno Nevada 89502
Research Site Westbury New York 11590
Research Site Greensboro North Carolina 27403
Research Site Cleveland Ohio 44106
Research Site Knoxville Tennessee 37920
Research Site Fairfax Virginia 22031
Research Site Milwaukee Wisconsin 64111

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07357597, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 21, 2026 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07357597 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →